Costa Rica signs agreement with AstraZeneca for supply of SARS-CoV-2 candidate vaccine
Agreement will allow the supply of one million doses of the candidate vaccine developed by the University of Oxford and AstraZeneca, starting in the first quarter of 2021. It would benefit half a million people, because two doses per person are required. With this, the country already has three agreements that would allow access to vaccines for a little more than three million people.
It is estimated that the vaccine will be available from the first quarter of 2021, if the clinical trials underway are successful and subject to approval by the regulatory agencies. Each dose will be priced at $4 (two doses per person), which does not include distribution costs that will be
Vaccine purchases would be made through the National Emergency Fund by way of exception allowed by Emergency Law 8488.
"This important advance in the task of preparing ourselves to vaccinate the population when vaccines become available is the result of the great work that the National Vaccine Commission has been doing and reflects our primary commitment to protect the health and life of citizens from the pandemic, using all the means at our disposal," said President Carlos Alvarado.